Clinical Trial

Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer

Suspended Phase 2
View on ClinicalTrials.gov →
Why the trial stopped
PI Request
Summary
To learn if the drug combination of BMS-986340, nivolumab, trifluridine/tipiracil, and bevacizumab can help to control advanced or metastatic MSS-CRC.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2025-06-05; most recent amendment 2026-07-14.
Status change: Recruiting → Suspended 2026-02-17
Status change: Not Yet Recruiting → Recruiting 2025-08-20
Trial Details
NCT Number NCT07011550
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: Strategic Alliance
Conditions Microsatellite-stable Colorectal Cancer, Standard of Care, Nivolumab, Bevacizumab
Enrollment 7 participants
Start Date 2025-08-15
Primary Completion 2028-07-01 (estimated)
Study Completion 2030-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-15